Effects of therapy in type 1 and type 2 diabetes mellitus with a peptide derived from islet neogenesis associated protein (INGAP). (Q45922414)

17 December 2017

title

Effects of therapy in type 1 and type 2 diabetes mellitus with a peptide derived from islet neogenesis associated protein (INGAP). (English)

1 reference

17 December 2017

0 references

2

1 reference

17 December 2017

Kathleen M Dungan

1

1 reference

17 December 2017

Robert E Ratner

series ordinal

3

1 reference

17 December 2017

publication date

1 September 2009

1 reference

17 December 2017

Diabetes - Metabolism: Research and Reviews

published in

1 reference

17 December 2017

volume

25

1 reference

17 December 2017

issue

6

1 reference

17 December 2017

page(s)

558-565

1 reference

17 December 2017

Prospects and challenges for islet regeneration as a treatment for diabetes: a review of islet neogenesis associated protein

cites work

1 reference

Beta-cell deficit and increased beta-cell apoptosis in humans with type 2 diabetes

21 January 2018

1 reference

7 January 2021

Cloning and sequencing of the pancreatic islet neogenesis associated protein (INGAP) gene and its expression in islet neogenesis in hamsters

1 reference

7 January 2021

The partial isolation and characterization of ilotropin, a novel islet-specific growth factor

1 reference

7 January 2021

Beta-cell mass plasticity in type 2 diabetes.

1 reference

7 January 2021

Acinar plasticity: development of a novel in vitro model to study human acinar-to-duct-to-islet differentiation

1 reference

7 January 2021

Evidence for the homeostatic regulation of induced beta cell mass expansion.

1 reference

7 January 2021

A pentadecapeptide fragment of islet neogenesis-associated protein increases beta-cell mass and reverses diabetes in C57BL/6J mice.

1 reference

7 January 2021

Intramuscular injection of islet neogenesis-associated protein peptide stimulates pancreatic islet neogenesis in healthy dogs

1 reference

7 January 2021

C-peptide is the appropriate outcome measure for type 1 diabetes clinical trials to preserve beta-cell function: report of an ADA workshop, 21-22 October 2001.

1 reference

7 January 2021

Rationale and methods for the estimation of insulin secretion in a given patient: from research to clinical practice

1 reference

7 January 2021

Mixed-meal tolerance test versus glucagon stimulation test for the assessment of beta-cell function in therapeutic trials in type 1 diabetes

1 reference

7 January 2021

The case for intravenous arginine stimulation in lieu of mixed-meal tolerance tests as outcome measure for intervention studies in recent-onset type 1 diabetes

1 reference

7 January 2021

Successful islet transplantation: continued insulin reserve provides long-term glycemic control

1 reference

7 January 2021

Correlations of in vivo beta-cell function tests with beta-cell mass and pancreatic insulin content in streptozocin-administered baboons.

1 reference

7 January 2021

1 reference

7 January 2021

Islet Neogenesis Associated Protein (INGAP) modulates gene expression in cultured neonatal rat islets.

1 reference

7 January 2021

GAD treatment and insulin secretion in recent-onset type 1 diabetes

1 reference

7 January 2021

Combination therapy with epidermal growth factor and gastrin induces neogenesis of human islet {beta}-cells from pancreatic duct cells and an increase in functional {beta}-cell mass

1 reference

7 January 2021

Glucagon-like peptide-1 and exendin-4 stimulate beta-cell neogenesis in streptozotocin-treated newborn rats resulting in persistently improved glucose homeostasis at adult age.

1 reference

7 January 2021

Identifiers

DOI

10.1002/DMRR.999

1 reference

17 December 2017

1 reference

17 December 2017